Here are the Form 4 insider transactions from United Therapeutics Corp (UTHR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow UTHR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UTHR filings page.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported a mix of option exercises and share trades in company stock. On May 26, 2026 she exercised stock options for 9,500 shares of common stock at a conversion price of $146.03 per share, then carried out open-market transactions involving 8,000 shares sold and 1,500 shares purchased, according to the filing’s transaction summary.
The open-market trades occurred at weighted average prices generally in the $560–$580 range per share. A footnote states these option exercises and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. Rothblatt also reports significant indirect holdings in family trusts and through a spouse, with individual trust positions such as 324,443 shares and 249,108 shares of common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported indirect gifts of company stock held through family trusts. The filing shows two bona fide gifts of Common Stock totaling 11,069 shares, made at a price of $0.00 per share.
After these gifts, one reporting trust holds 8,902 shares of United Therapeutics Common Stock and another trust holds 249,108 shares, both reported as indirect ownership. Additional indirect holdings disclosed include 45,596 shares and 324,443 shares held by family trusts, and 166 shares held by a spouse. These are non-market, gratuitous transfers and not open-market sales.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On May 22, 2026, she exercised stock options for 9,500 shares of common stock at $146.03 per share and sold 9,500 shares in open-market trades at prices around $563–$570 per share.
The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which remains in effect until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. After the transactions, she held 40,513 shares of common stock directly, plus additional indirect holdings through various family trusts and a small position held by her spouse.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported a series of insider transactions in the company’s common stock. On May 21, 2026, he exercised 10,000 stock options at an exercise price of $117.76 per share, converting them into common shares.
That same day, he executed multiple open-market sales totaling 10,000 shares at prices in the mid‑$560s, with trades reported at weighted average prices such as $566.12 and $563.12. The filing states these transactions were carried out under a Rule 10b5‑1 trading plan entered into on October 31, 2025, indicating they were pre‑scheduled.
After these transactions, Edgemond directly owns 18,876 shares of United Therapeutics common stock and holds 70,000 stock options following the 10,000‑share option exercise.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported option exercises and related share sales in United Therapeutics common stock. On 2026-05-21, she exercised 9,500 stock options at an exercise price of $146.03 per share, receiving an equal number of common shares.
That same day, she sold 9,500 common shares in multiple open-market transactions at weighted average prices generally between about $560 and $566, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly held 40,513 common shares and also had additional indirect holdings through various family trusts and a spouse account.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported an option exercise and related share sales. On May 20, 2026, she exercised stock options for 9,500 shares of common stock at a strike price of $146.03 per share and sold 9,500 shares in multiple open-market transactions at prices generally in the $561–$578 range.
These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026. Following the transactions, she directly holds 40,513 common shares and also has indirect holdings through several family trusts and a spouse account.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares of Common Stock in pre-planned trades. On May 21, 2026, the EVP & General Counsel exercised options covering 8,300 shares at a conversion price of $146.03 per share and sold 8,300 shares in multiple open-market transactions at weighted-average prices in the mid-$560s. These trades were executed pursuant to a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After the transactions, Mahon directly holds 45,172 shares of UNITED THERAPEUTICS Common Stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an option exercise and related share sales. On May 19, 2026, she exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in multiple open-market transactions at weighted average prices generally around $561–$572 per share. The filing states these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 options expiring on March 17, 2027 or December 31, 2026. Rothblatt also reports indirect ownership of additional common shares through various family trusts and her spouse.
United Therapeutics CFO and Treasurer James Edgemond reported a combination of stock option exercises and share sales in the company’s common stock. On May 18, 2026, he exercised options for 10,000 shares at strike prices of $117.76 and $135.42 per share, then sold 10,000 shares in multiple open-market transactions at prices between approximately $562.91 and $570.18. The filing states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025, and he continues to hold United Therapeutics common stock following the activity.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported a combination of stock option exercise and pre-planned share sales. She exercised stock options covering 9,500 shares of common stock at a $146.03 exercise price and sold 9,500 shares in multiple open-market trades at weighted average prices around $565–$570 per share. These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which allows up to the exercise of 1,734,410 stock options expiring on March 17, 2027, or runs until December 31, 2026, whichever occurs first. Following the reported transactions, she directly holds 40,513 shares of common stock, in addition to indirect holdings through family trusts and her spouse.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and sold the resulting shares in multiple open-market transactions on May 15, 2026 under a pre-arranged Rule 10b5-1 trading plan.
Following these transactions, Rothblatt directly holds 40,513 shares of common stock and also has additional indirect holdings through various family trusts and a spouse account. The 10b5-1 plan, adopted on November 7, 2025, will continue until the earlier of the exercise of 1,734,410 stock options that expire on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold the resulting common shares under a pre-arranged Rule 10b5-1 trading plan. She exercised 9,500 stock options at an exercise price of $146.03 per share and received an equal number of common shares.
On the same date, she sold 9,500 common shares in multiple open-market transactions at prices generally between about $570.51 and $578.68 per share, leaving 50,013 common shares held directly. Additional common shares are held indirectly through various family trusts and by her spouse, as disclosed in the footnotes.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported an exercise-and-sale transaction in company stock. He exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and, on the same date, sold 10,000 shares in multiple open-market trades at weighted average prices generally between about $568 and $579 per share. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, he directly holds 18,876 shares of Common Stock.
UNITED THERAPEUTICS Corp President and COO Michael Benkowitz reported gifting stock options rather than trading shares in the market. He made two bona fide gift transfers of stock options covering a total of 23,456 underlying shares of common stock, split into 11,728 options from direct holdings and 11,728 options from indirect holdings.
Each option has an exercise price of $217.50 per share and an expiration date of March 15, 2033. After the indirect gift, 99,720 stock options are shown as held indirectly in trusts beneficially owned by him, for which he has sole investment and voting power. Code G indicates these are non‑sale, bona fide gifts rather than open‑market sales.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised 9,500 stock options at an exercise price of $146.03 per share and sold 9,500 common shares in multiple open‑market trades at weighted average prices around $575–$584. These transactions were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025.
After the transactions, Rothblatt holds 40,513 common shares directly, additional shares indirectly through family trusts and a spouse, and 240,410 stock options expiring on March 17, 2027.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. On May 12, 2026, she exercised 9,500 stock options at $146.03 per share to acquire common stock, then sold 9,500 shares in multiple open-market trades around $570–$583 per share.
The filing states these moves were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the transactions, Rothblatt directly holds 40,513 shares of common stock and also has additional indirect holdings through family trusts and her spouse. The trading plan will continue until the earlier of the exercise of 1,734,410 stock options, which expire on March 17, 2027, or December 31, 2026.
UNITED THERAPEUTICS Corp director Nilda Mesa sold shares in an open‑market transaction. On this trade, Mesa sold 258 shares of common stock at a price of $581.935 per share. After the sale, Mesa directly owned 5,028 shares of UNITED THERAPEUTICS common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported exercising stock options for 9,500 shares of common stock at an exercise price of $146.03 per share on May 11, 2026, then selling 9,500 shares in multiple open‑market transactions.
The sales occurred at weighted average prices generally between about $568.89 and $580.45 per share, with individual trades reported around the high‑$560s to low‑$580s. According to a footnote, this exercise and sale sequence was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is scheduled to continue until up to 1,734,410 stock options expiring on March 17, 2027 are exercised or until December 31, 2026, whichever comes first.
Rothblatt also reports significant indirect holdings of UNITED THERAPEUTICS common stock through various family trusts and through a spouse, reflecting additional long‑term exposure separate from the directly held shares involved in these transactions.
United Therapeutics CFO and Treasurer James Edgemond reported an exercise-and-sell transaction in company common stock. On May 11, he exercised stock options for 10,000 shares at $135.42 per share and sold 10,000 shares in multiple open-market trades around the $570–$580 range under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 18,876 shares of common stock and 12,500 stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. She exercised stock options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in multiple open-market trades on May 8, 2026 at weighted average prices generally between the high $560s and low $570s per share. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026. After these transactions, Rothblatt directly holds 40,513 shares of common stock and has additional indirect holdings through various family trusts and her spouse.
United Therapeutics Corp CFO and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. On May 7, 2026, he exercised stock options to acquire 10,000 shares of Common Stock at an exercise price of $135.42 per share and sold 10,000 shares of Common Stock in a series of open-market sales at prices around the high-$500 range per share. The filing notes that the option exercise and subsequent sales were carried out under a pre-arranged Rule 10b5-1 trading plan, indicating the trades were scheduled in advance rather than timed discretionarily.
United Therapeutics Chairperson and CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On May 7, 2026, she exercised 9,500 stock options at $146.03 per share and sold 9,500 common shares in multiple open‑market trades under a pre‑arranged Rule 10b5‑1 trading plan.
After these transactions, she directly holds 49,513 common shares and also has additional indirect holdings through family trusts and her spouse.
United Therapeutics executive vice president and general counsel Paul A. Mahon exercised stock options and sold the resulting shares in a planned transaction. On May 7, 2026, he exercised options for 8,300 shares of common stock at a strike price of $146.03 per share and carried out open‑market sales totaling 8,300 shares.
The sales were executed in multiple trades at prices including about $597.54, $596.19, $588.51 and several weighted‑average prices in the mid‑$580s, according to footnotes. The filing states these transactions were made under a pre‑arranged Rule 10b5‑1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sell transaction in company stock. She exercised stock options to acquire 9,500 shares of common stock at $146.03 per share, then sold 9,500 shares in multiple open-market trades, including 1,513 shares at $595.02 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The filing also lists substantial indirect holdings in family trusts and by her spouse.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options and sold common shares in a planned sequence. On May 5, 2026, she exercised 9,500 stock options at $146.03 per share and sold 9,500 common shares in multiple open-market trades around the high-$500s.
The filing shows these actions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, designed to run until the earlier of exercising 1,734,410 options expiring on March 17, 2027 or December 31, 2026. After the transactions, she directly holds 40,513 common shares and also has additional indirect holdings through various family trusts and a spouse account.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options to acquire 9,500 shares of common stock at $146.03 per share, then sold 9,500 shares in multiple open‑market trades at prices between roughly $568 and $583. These transactions were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025.
After the transactions, she held 49,973 shares directly and maintained substantial indirect holdings through family trusts and her spouse, including 324,443, 258,117 and 45,596 shares. The trading plan will continue until either 1,734,410 stock options expiring on March 17, 2027 are exercised or December 31, 2026, whichever occurs first.
UNITED THERAPEUTICS Corp Chief Financial Officer and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. On May 4, 2026, he exercised stock options to acquire 10,000 shares of common stock at a strike price of $135.42 per share and sold 10,000 shares in multiple open-market trades at prices generally between the high $560s and low $580s per share. The filing states these trades were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025, indicating the timing was scheduled in advance. After the transactions, Edgemond continues to hold 18,876 shares of common stock directly, along with 32,500 stock options, signaling he retains a meaningful equity stake in UNITED THERAPEUTICS.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at $146.03 per share and sold 9,500 shares in open-market trades on May 1, 2026. The sales occurred at prices around $565.78–$571.95 per share in multiple transactions.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until up to 1,734,410 options are exercised or until December 31, 2026. Following the transactions, Rothblatt holds 40,513 shares directly, plus additional indirect holdings through family trusts and a spouse account.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options and sold shares in a pre-planned transaction. On April 30, 2026, she exercised 9,500 stock options at $146.03 per share and sold 9,500 shares of common stock in open-market trades at prices such as $579.51 and $570.76 per share.
The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. After the transactions, Rothblatt holds 50,013 common shares directly and also has indirect ownership through family trusts and a spouse account, including 324,443 shares, 258,117 shares, 45,596 shares, 10,962 shares held by trusts, and 166 shares held by her spouse.
UNITED THERAPEUTICS Corp CFO James Edgemond exercised and sold shares in a planned transaction. On April 30, 2026, he exercised 10,000 stock options for Common Stock at a strike price of $135.42 per share and then sold 10,000 shares in a series of open-market trades at prices reported between $569.24 and $578.76 per share.
These actions were made under a Rule 10b5-1 trading plan entered into on October 31, 2025. After the transactions, he directly owned 18,876 shares of United Therapeutics common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at $146.03 per share and sold 9,500 common shares in multiple open-market trades at prices ranging from about $565.10 to $574.31. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising up to 1,734,410 options expiring in March 2027 or December 31, 2026. After these transactions, she holds 50,013 common shares directly, additional common shares indirectly through various family trusts and her spouse, and 91,288 stock options remain outstanding.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at $146.03 per share and, on the same day, sold 9,500 shares in multiple open-market transactions around $565–$572 per share.
These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After the trades, Rothblatt directly owns 40,513 common shares and also has additional indirect holdings through family trusts and a spouse account.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, then sold 9,500 shares in multiple open-market trades at prices around $565–$572.42 per share.
The filing shows this exercise-and-sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which runs until either 1,734,410 stock options expiring on March 17, 2027 are exercised or until December 31, 2026. After these transactions, Rothblatt directly owns 40,513 shares of common stock, alongside additional indirect holdings through family trusts and a spouse account.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. On April 27, 2026, he exercised 10,000 stock options at $135.42 per share and sold 10,000 common shares in multiple open-market trades at weighted-average prices around $565–$572, under a Rule 10b5-1 trading plan entered into on October 31, 2025. After these transactions, he directly holds 18,876 common shares and 52,500 stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an option exercise and related share sales. On April 24, 2026, she exercised stock options covering 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in multiple open‑market transactions at prices generally around the mid‑$560s per share. These transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following the trades, she directly holds 40,513 shares of common stock and also has substantial indirect holdings through various family trusts. The trading plan remains in place until the earlier of the exercise of up to 1,734,410 stock options, all expiring on March 17, 2027, or December 31, 2026.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options to acquire 10,000 shares of common stock at a strike price of $135.42 per share, then sold 10,000 shares in open-market trades on April 22–23, 2026 under a Rule 10b5-1 trading plan.
Sale prices for the common stock ranged around the mid-$570s per share across multiple trades. Following these transactions, he directly holds 18,876 shares of United Therapeutics common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise of stock options and related share sales. She exercised stock options for 9,500 shares of common stock at a conversion price of $146.03 per share and sold 9,500 shares in multiple open-market transactions at weighted average prices in the mid-$570 range, all under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 50,013 shares of common stock directly and continues to hold significant indirect positions through family trusts and her spouse, including 324,443 and 258,117 shares in two family trusts. The Rule 10b5-1 plan remains in place until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp director Christopher Patusky exercised and sold company stock under a pre-set plan. He exercised stock options for 2,910 shares of common stock at $101.80 per share and, on the same day, sold 2,910 shares at $569.00 per share in an open-market transaction.
The filing states these transactions were carried out under a Rule 10b5-1 trading plan entered into on December 18, 2025. After the sale, he held 1,490 shares directly and 1,100 shares indirectly through a trust, and the exercised stock option covering 2,910 shares was fully used.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported exercising stock options and selling resulting shares of common stock under a pre-arranged Rule 10b5-1 trading plan. The plan, adopted on November 7, 2025, continues until either 1,734,410 options expiring on March 17, 2027 are exercised or until December 31, 2026.
Rothblatt exercised 9,500 stock options at $146.03 per share, acquiring the same number of common shares. On the same date, she executed multiple open-market sales totaling 9,500 common shares at weighted average prices generally between the high $572 and $580 per-share range.
Following these transactions, Rothblatt directly holds 40,513 shares of common stock, with additional shares held indirectly through various family trusts and by her spouse as described in the filing. The open-market sales and option exercise form part of the ongoing 10b5-1 trading plan rather than discretionary, one-off trades.
United Therapeutics Chairperson and CEO Martine A. Rothblatt reported an exercise-and-sell transaction in company common stock. On April 21, 2026, she exercised stock options to acquire 9,500 shares at an exercise price of $146.03 per share and sold the same 9,500 shares in multiple open-market trades at prices generally between the mid-$560s and mid-$570s per share.
The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026. Following the trades, Rothblatt directly holds 49,854 shares and also has indirect ownership through family trusts and spouse accounts, including trust positions such as 324,443 shares of common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an option exercise and related share sales. On April 20, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share and sold 9,500 shares of common stock in multiple open-market transactions.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, with trade prices generally in the low-to-high $570s per share. After these transactions, she directly holds 40,513 common shares and also has additional indirect holdings through family trusts and her spouse. The 10b5-1 plan contemplates the exercise of up to 1,734,410 stock options that expire on March 17, 2027, or will terminate earlier on December 31, 2026.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. On April 20, 2026, he exercised 10,000 stock options at $135.42 per share to acquire common stock, then sold 10,000 shares in open‑market trades at prices ranging from about $571.79 to $585.80. The filing shows he now directly holds 18,876 shares of common stock. The transactions were executed under a pre‑arranged Rule 10b5-1 trading plan.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On April 17, 2026, she exercised 9,500 stock options at a conversion price of $146.03 per share and acquired an equal number of common shares.
The same day, she sold 9,500 common shares in multiple open-market trades at prices generally around the high-$570s to low-$590s per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she directly holds 40,513 common shares and 17,000 stock options, and also has additional indirect holdings through several family trusts and her spouse.
UNITED THERAPEUTICS director Christopher Patusky exercised stock options and sold shares in a planned transaction. He exercised 1,000 stock options at an exercise price of $101.80 per share, then sold 1,000 common shares at $578.88 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he holds 1,490 common shares directly and 1,100 shares indirectly through a trust.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold shares in a pre-planned transaction. She exercised 9,500 stock options for common stock at an exercise price of $146.03 per share and acquired 9,500 common shares.
On the same date, she sold 9,500 common shares in multiple open-market trades at prices between $573.9595 and $581.3325. These trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 options expiring on March 17, 2027 or December 31, 2026. After these transactions, she holds 40,513 shares directly, plus additional indirect holdings including 166 shares held by a spouse and 324,443 shares held by family trusts.
UNITED THERAPEUTICS Corp CFO James Edgemond exercised stock options for 10,000 shares of Common Stock at an exercise price of $135.42 per share and sold 10,000 shares in open-market transactions. The sales occurred on April 16, 2026 in multiple trades at prices reported between $573.9146 and $581.6400 per share.
The filing states that this option exercise and subsequent share sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. After these transactions, Edgemond directly holds 18,876 shares of Common Stock and 82,500 stock options.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported a planned combination of option exercises and share sales. She exercised stock options for 19,000 shares of common stock at an exercise price of $146.03 per share, then sold 19,075 shares in multiple open-market trades at prices mostly around the high-$570s to low-$580s.
After these direct transactions, she holds 40,513 common shares directly. In addition, indirect holdings include shares held by family trusts and her spouse, with trust and spouse positions ranging from 10,962 to 258,117 shares as of March 13, 2026. The filing notes that the option exercises and resulting sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised stock options and sold shares in a planned transaction. As EVP & General Counsel, he exercised options for 8,300 shares of common stock at an exercise price of $146.03 per share, then sold 8,300 shares in multiple open-market trades at weighted average prices around $574–$578 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on August 11, 2025. After the trades, he directly owned 45,172 shares of United Therapeutics common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and acquired the corresponding common shares.
On the same date, she sold 9,500 common shares in multiple open-market transactions, with reported prices including $569.7771, $571.3888 and up to $579.5260 per share, under a pre-arranged Rule 10b5-1 trading plan. Following these trades, she holds 40,513 common shares directly, in addition to indirect holdings by her spouse and in family trusts.
United Therapeutics Corp CFO and Treasurer James Edgemond exercised stock options and sold shares in a planned transaction. He exercised options for 10,000 shares of common stock at an exercise price of $135.42 per share and then sold 10,000 shares in open-market trades at prices ranging from about $569.28 to $580.03. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. After the sales, he directly holds 18,876 shares of United Therapeutics common stock.